NASDAQ:CALC

CalciMedica Q2 2025 Earnings Results & Report

CalciMedica logo
$1.17 -0.05 (-4.10%)
Closing price 04:00 PM Eastern
Extended Trading
$1.16 -0.01 (-0.85%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CalciMedica met analyst earnings expectations in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$2.00 versus the -$2.00 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens

CalciMedica EPS Results

Actual EPS
-$2.00
Consensus EPS
-$2.00
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

CalciMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

CalciMedica Q2 2025 Earnings FAQ

CalciMedica (NASDAQ:CALC) reported earnings of -$2.00 per share for Q2 2025, matching the consensus estimate of -$2.00. The report was announced on Tuesday, August 12, 2025.

CalciMedica Earnings Headlines

FY2026 EPS Estimates for CalciMedica Raised by HC Wainwright
Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
CalciMedica (CALC) Set to Release Earnings on Wednesday
See More CalciMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email.

About CalciMedica

CalciMedica (NASDAQ:CALC) is a clinical-stage biopharmaceutical company developing treatments for serious inflammatory and immunologic conditions. Its research focuses on calcium release-activated calcium (CRAC) channels, which play a role in immune-cell activity and inflammation.

The company’s lead drug candidate, Auxora, is an investigational CRAC channel inhibitor being studied for acute inflammatory conditions, including acute pancreatitis. CalciMedica has no marketed products; its candidates remain in clinical development.

Based in La Jolla, California, CalciMedica became a publicly traded company in 2024 through a business combination with Orion Acquisition Corp. The company’s work is centered on developing and testing its therapies, rather than commercial product sales.

View CalciMedica Profile